"In it (the 6/18 email) Leo said he figured he could update on the results of the FDA meeting mid to late July, which he did on 7/20." Yes, he did. Specifically "I figure by mid -late July i'll be able to update shareholders with the results of the meeting."
"He then said that when he updates on B that he would give a broader update in general." Specifically: "When I update on Brilacidin I will do a complete corporate update as well."
That update on B was the 7/20 press release ( http://cellceutix.com/cellceutix-to-start-brilacidin-phase-3-program-in-absssi/ ). It didn't include a broader update in general. One could then argue that the 7/20 press release SHOULD HAVE included a broader update ("When I update on Brilacidin I will do a complete corporate update as well.").
So the bottom line appears to be that, while there was no statement made to the effect that a "complete corporate update" would be provided by the end of July, it was clearly implied that that would happen based on the CEO tying the timing to the Brilacidin meeting update. So one could reasonably conclude that a complete corporate update is due but the occasion on which it was supposed to occur, concurrent with the Brilacidin meeting update, is long past and so today, July 30, is not a special date when it comes to that broader update.